Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer

Sun,Mei; Jiang,Rui; Wang,Guan; Zhang,Chao; Li,Jindong; Jin,Chengyan; Zhang,Xingyi

doi:10.3892/ijo.2013.1813

Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer

Authors:
- Mei Sun
- Rui Jiang
- Guan Wang
- Chao Zhang
- Jindong Li
- Chengyan Jin
- Xingyi Zhang
View Affiliations

Affiliations: Department of Pathology, The Second Hospital of Jilin University, Changchun 130041, P.R. China, Department of Orthopedic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, P.R. China, Department of Cardiac Medicine, The Second Hospital of Jilin University, Changchun 130041, P.R. China, Department of Ophthalmology, The Second Hospital of Jilin University, Changchun 130041, P.R. China, Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun 130041, P.R. China
Published online on: February 8, 2013 https://doi.org/10.3892/ijo.2013.1813
Pages: 1376-1382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1), a growth suppressor that negatively regulates CDK2 activity, has been implicated in various types of cancer; yet its role in lung cancer remains unclear. In the present study, a lentivirus-based system was used to specifically downregulate or upregulate CDK2AP1 expression. A549 lung cancer cells were treated with RNAi (RNA interference) or lentiviral vectors for overexpression. Ectopic overexpression of CDK2AP1 in A549 cells in vitro greatly impaired their proliferation and colony-forming ability and enhanced their chemosensitivity to cisplatin and paclitaxel and caused cell cycle arrest at G1/S transition accompanied by the reduction of expression of CDK4 and CDK7. Injection of the ectopically CDK2AP1-overexpressing A549 cells into nude mice resulted in growth arrest of solid lung cancer tumors in vivo. Knockdown of CDK2AP1 in A549 cells, however, gave rise to the opposite effects including promoting cell proliferation/growth, cell cycling in vitro and enhancing tumorigenesis in vivo. These results suggest that CDK2AP1 plays an important role in modulating the growth and tumorigenesis of lung cancer cells and also has significant effects on the chemosensitivity of pulmonary malignancies to chemotherapeutics. Hence, this study extends our knowledge on the relationship between CDK2AP1 and oncogenesis of lung cancer, indicating that CDK2AP1 may serve as a new molecular target for future lung cancer therapy.

View Figures

View References

1	Sun M, Jiang R, Li JD, et al: MED19 promotes proliferation and tumorigenesis of lung cancer. Mol Cell Biochem. 355:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wang CG, Wang RY, Sun M, Li JD, Gao N and Zhang XY: In vivo antitumor effect of siRNA against STAT3 on transplanted Lewis lung cancer in mice. Chem Res Chin Univ. 24:322–329. 2008.
3	Luo SL, Sun M, Jiamg R, Wang G and Zhang XY: Establishment of primary mouse lung adenocarcinoma cell culture. Oncol Lett. 2:629–632. 2011.PubMed/NCBI
4	Eymin B and Gazzeri S: Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr. 4:114–123. 2010. View Article : Google Scholar : PubMed/NCBI
5	Shintani S, Mihara M, Terakado N, et al: Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res. 7:2776–2782. 2001.PubMed/NCBI
6	Shintani S, Ohyama H, Zhang X, et al: p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol. 20:6300–6307. 2000. View Article : Google Scholar : PubMed/NCBI
7	Todd R, McBride J, Tsuji T, et al: Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J. 9:1362–1370. 1995.PubMed/NCBI
8	Daigo Y, Suzuki K, Maruyama O, et al: Isolation, mapping and mutation analysis of a human cDNA homologous to the doc-1 gene of the Chinese hamster, a candidate tumor suppressor for oral cancer. Genes Chromosomes Cancer. 20:204–207. 1997. View Article : Google Scholar : PubMed/NCBI
9	Peng H, Shintani S, Kim Y and Wong DT: Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway. Neoplasia. 8:1028–1036. 2006. View Article : Google Scholar : PubMed/NCBI
10	Hiyoshi Y, Watanabe M, Hirashima K, et al: p12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma. Oncol Rep. 22:35–39. 2009.PubMed/NCBI
11	Zolochevska O and Figueiredo ML: Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function. Prostate. 69:1586–1597. 2009. View Article : Google Scholar : PubMed/NCBI
12	Zolochevska O and Figueiredo ML: Expression of cell cycle regulator cdk2ap1 suppresses tumor cell phenotype by non-cell-autonomous mechanisms. Oral Oncol. 45:e106–112. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zolochevska O and Figueiredo ML: Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells. Prostate. 71:353–367. 2011. View Article : Google Scholar : PubMed/NCBI
14	Choi MG, Sohn TS, Park SB, et al: Decreased expression of p12 is associated with more advanced tumor invasion in human gastric cancer tissues. Eur Surg Res. 42:223–229. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yuan Z, Gaba AG, Kent TS, Bennett A, Miller A and Weber TK: Modulation of CDK2-AP1 [p12(DOC-1)] expression in human colorectal cancer. Oncogene. 24:3657–3668. 2005.PubMed/NCBI
16	Figueiredo ML, Kim Y, St John MA and Wong DT: p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer. Clin Cancer Res. 11:3939–3948. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cwikla SJ, Tsuji T, McBride J, Wong DT and Todd R: doc-1-mediated apoptosis in malignant hamster oral keratinocytes. J Oral Maxillofac Surg. 58:406–414. 2000. View Article : Google Scholar : PubMed/NCBI
18	Galetta D, Pisconti S, Cinieri S, et al: Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE). Clin Lung Cancer. 12:402–406. 2011.
19	Zolochevska O and Figueiredo ML: Novel tumor growth inhibition mechanism by cell cycle regulator cdk2ap1 involves antiangiogenesis modulation. Microvasc Res. 80:324–331. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wong DT, Kim JJ, Khalid O, Sun HH and Kim Y: Double edge: CDK2AP1 in cell-cycle regulation and epigenetic regulation. J Dent Res. 91:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zheng J, Xue H, Wang T, et al: miR-21 downregulates the tumor suppressor P12 CDK2AP1 and stimulates cell proliferation and invasion. J Cell Biochem. 112:872–880. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kim Y, McBride J, Kimlin L, Pae EK, Deshpande A and Wong DT: Targeted inactivation of p12, CDK2 associating protein 1, leads to early embryonic lethality. PLoS One. 4:e45182009. View Article : Google Scholar : PubMed/NCBI
23	Wadler S: Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat. 4:347–367. 2001. View Article : Google Scholar : PubMed/NCBI
24	Yang TY, Chang GC, Chen KC, et al: Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur J Pharmacol. 663:17–26. 2011. View Article : Google Scholar : PubMed/NCBI
25	Kim Y, McBride J, Zhang R, Zhou X and Wong DT: p12(CDK2-AP1) mediates DNA damage responses induced by cisplatin. Oncogene. 24:407–418. 2005. View Article : Google Scholar : PubMed/NCBI